Regular clinical monitoring is still recommended, particularly with newer peptides
18 For example, Novo Nordisks Rybelsus (oral semaglutide) reached its NCE-1 date on December 5, 2021, opening the door for the first wave of generic challenges
GLP-1 medications like semaglutide and tirzepatide have become widely used among women for weight loss, but the conversation around how they interact with estrogen, insulin, the menstrual cycle, thyroid function, and fertility is still catching up to the pace of prescribing
Katsurada K, Yada T
For the first time, large numbers of patients are achieving sustained, clinically-significant weight loss, often 15 to 20 per cent of body weight in under a year